Advertisement
Manufacturing and Capabilities
Subscribe to Manufacturing and Capabilities

The Lead

Elanco Animal Health, Dow AgroSciences Announce Strategic R&D Agreement

September 18, 2014 9:09 am | News | Comments

Elanco, the animal health division of Eli Lilly and Company, and Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company, are announcing a strategic R&D agreement that will focus on developing integrated solutions to enable livestock producers to increase meat and milk production to meet the demands of the growing global population.

EMD Serono and Sutro Biopharma Announce $298M Deal to Develop Antibody Drug Conjugates

September 17, 2014 8:14 am | News | Comments

EMD Serono and Sutro Biopharma announced a collaboration and license agreement to develop...

MedGenesis Enters Into Agreement with Pfizer for Potential Treatments for Parkinson's Disease

September 16, 2014 9:07 am | News | Comments

MedGenesis Therapeutix has entered into an agreement with Pfizer, granting Pfizer an exclusive,...

Mylan Commences Clinical Trials for Generic Versions of Advair Diskus and Insulin Analog to Lantus

September 16, 2014 8:59 am | News | Comments

Mylan today announced it is initiating Phase III clinical trials for its generic version of...

View Sample

FREE Email Newsletter

The Future of Chemicals: Managing Complexity and Enabling Growth with Natural Supply Chains

September 16, 2014 8:45 am | by Rohit Singh, Principal, Strategy; and Marc Waco, Partner, PwC US Chemicals Advisory Leader | Blogs | Comments

In an increasingly complex and challenging climate, chemical companies are facing a combination of shifting market forces and an increasingly heterogeneous customer set. Many organizations are focusing solely on all-out growth or across-the-board cost-cutting strategies in an attempt to adjust course.

AstraZeneca and Lilly to Develop and Commercialize Alzheimer’s Disease Treatment

September 16, 2014 8:39 am | News | Comments

AstraZeneca and Eli Lilly announced an agreement to jointly develop and commercialize AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer’s disease.  

U.S. Government, WHO Seek Ways to Expand Production of Ebola Drugs, Vaccines

September 15, 2014 8:20 am | by Helen Branswell, The Canadian Press | News | Comments

High level efforts are underway to find ways to substantially ramp up production of experimental Ebola vaccines and drugs, officials at the World Health Organization and within the U.S. government say.         

Advertisement

FDA Accepts Tuzistra XR NDA for Full Review

September 15, 2014 8:12 am | News | Comments

Vernalis and Tris Pharma announced that the FDA has confirmed that the New Drug Application for Tuzistra XR has been accepted for full review. This triggers a milestone payment from Vernalis to Tris.        

Gilead to License Generic Version of Sovaldi

September 15, 2014 8:07 am | by The Associated Press | News | Comments

Gilead Sciences says it has reached a deal with several generic drugmakers to produce cheaper versions of its popular, expensive hepatitis C drug Sovaldi for use in developing countries.           

Center for Advanced Cellular Therapeutics to Rise on Penn Medicine Campus

September 12, 2014 8:09 am | News | Comments

The University of Pennsylvania today reached an important milestone in its alliance with Novartis as it unveiled plans for the construction of a first-of-its-kind Center for Advanced Cellular Therapeutics (CACT) on the Penn Medicine campus in Philadelphia.

Oxygen Biotherapeutics Announces Halt of Oxycyte Phase IIb Traumatic Brain Injury Trial

September 12, 2014 8:01 am | News | Comments

Oxygen Biotherapeutics has elected to stop the current Phase IIb trial for its Oxycyte drug candidate and consider strategic alternatives for the program moving forward. The company will review the data generated on the patients enrolled in the trial to date.

A Tale of Two Cities - SAFC's Irvine, Scotland and Lenexa, KS Dry Powder Media Facilities

September 11, 2014 1:38 pm | by Mike Auerbach, Editor In Chief | Articles | Comments

SAFC, a global company that supplies a multitude of services to the biopharm/pharmaceutical industry has recently opened a new Dry Powder Media (DPM ) manufacturing facility in Irvine, Scotland to complement their Lenexa, KS DPM facility. By doing so SAFC has shown their commitment to their customers and this growing segment of the pharmaceutical industry.

Advertisement

Baxter Announces Baxalta as the Name of New Global Biopharmaceutical Company

September 11, 2014 8:37 am | News | Comments

Baxter International has announced that Baxalta Incorporated will be the name of the new, publicly traded biopharmaceutical company that is expected to launch in mid-2015.             

Seattle Genetics and Genmab Enter Into Antibody-Drug Conjugate Collaboration

September 10, 2014 8:25 am | News | Comments

Under the new agreement, Genmab will pay an upfront fee of $11M for exclusive rights to utilize Seattle Genetics' auristatin-based ADC technology with Genmab'sHuMax(R)-AXL, an antibody targeting AXL which is expressed on multiple types of solid cancers.

Valeant Pharmaceuticals Expands Bausch + Lomb Manufacturing Facility, Adding 120 New Jobs in Rochester, NY

September 9, 2014 8:39 am | News | Comments

Valeant Pharmaceuticals hosted a ribbon cutting ceremony for the new Bausch + Lomb ULTRA contact lens manufacturing lines and solar array assembly at the company's Optics Center in Rochester, NY. The ceremony recognized the expansion and installation of the new manufacturing lines, which will produce the company's silicone hydrogel contact lens, Bausch + Lomb ULTRA.

Shortage of Bladder Cancer Drug Could be Tragic for Patients, Doctor Says

September 9, 2014 8:32 am | by Sheryl Ubelacker, The Canadian Press | News | Comments

The shortage of the medication — called bacillus Calmette-Guerin, or BCG — has been caused by manufacturing problems at plants operated by two different pharmaceutical companies — Merck and Sanofi Pasteur.        

Reynolds Taking Nicotine Gum National

September 4, 2014 9:55 am | by MICHAEL FELBERBAUM, AP Tobacco Writer | News | Comments

Cigarette maker Reynolds American Inc. is taking its Zonnic brand nicotine gum nationwide, challenging the pharmaceutical industry's hold and pricing power of the market for products to help people stop smoking.       

Advertisement

AMRI Expands Services to Protein Market

September 4, 2014 9:07 am | News | Comments

AMRI announced today that it has expanded into the protein market, with an initial focus on protein expression and purification. The global revenue of the total proteomics market is anticipated to grow at a compound annual growth rate of about 4.1% to about $9.2 billion by 2018.

Johnson & Johnson to Accelerate Ebola Vaccine Program

September 4, 2014 8:43 am | News | Comments

Johnson & Johnson will fast-track the development of a promising new combination vaccine regimen against Ebola and broadly collaborate with its partners in global health to deliver immediate relief aid to address the current Ebola outbreak.

MEDA Sells NJ Facility to DPT

September 4, 2014 8:17 am | News | Comments

Meda has signed an agreement to divest the manufacturing unit in Lakewood, New Jersey, to the contract manufacturer DPT. The manufacturing facility is dedicated to global supply of the product MUSE.         

Google's Health Startup Forges Venture with AbbVie

September 3, 2014 3:24 pm | News | Comments

Google's ambitious health startup is teaming up with biotechnology drugmaker AbbVie in a $500 million joint venture that will try to develop new ways to treat cancer and other diseases such as Alzheimer's.        

AstraZeneca and Redx Pharma to Collaborate on Targeting Genetic Drivers of Tumor Growth

September 3, 2014 8:54 am | News | Comments

AstraZeneca has entered into a research collaboration with Redx Pharma Limited to discover and develop new molecules targeting a genetic driver of tumor growth and survival. The research will complement AstraZeneca’s strategic approach focused on genetic drivers of cancer and mechanisms of resistance to established and novel cancer therapies.

Infinity and AbbVie to Develop and Commercialize Cancer Treatment

September 3, 2014 8:28 am | News | Comments

Under the terms of the agreement, Infinity will receive an upfront payment of $275 million and is eligible to receive up to $530 million in additional payments for the achievement of development, regulatory and commercial milestones, including up to $405 million for the achievement of milestones through the first commercial sale of duvelisib.

Particle Sciences Expands Drug Eluting Device Capabilities and Overall Clinical Trial Manufacturing Resources

September 2, 2014 2:39 pm | News | Comments

Particle Sciences, a CDMO for drug eluting devices, has added to its investment in development and manufacturing capabilities with the addition of a new 18mm extruder. The company now has over 6000ft2 of operating cleanroom and cGMP warehouse space including ISO5 (sterile) and two dedicated highly potent suites.

Experimental Ebola Drug Heals All Monkeys in Study

September 2, 2014 8:43 am | by MARILYNN MARCHIONE, AP Chief Medical Writer | News | Comments

The monkeys were given the drug, ZMapp, three to five days after they were infected with the virus and when most were showing symptoms. That is several days later than any other experimental Ebola treatment tested so far.     

Virginia Facility Processes Crab Blood for Medical Tests

September 2, 2014 8:19 am | by CONNIE MORRISON, Eastern Shore News | News | Comments

Wako Chemicals' Cape Charles facility extracts the naturally pale blue blood of horseshoe crabs and processes it to yield a protein used in the medical industry to test instruments, implants and pharmaceuticals.       

Merck Serono Breaks Ground for New Pharmaceutical Manufacturing Facility in China

August 28, 2014 10:48 am | News | Comments

The new facility, which will be the group's second-largest pharmaceutical manufacturing facility worldwide, will focus on the bulk production and packaging of Glucophage®, Concor® and Euthyrox®, Merck Serono's leading brands for the treatment of diabetes, cardiovascular diseases and thyroid disorders, respectively.

IBM’s Watson Ushers in a New Era of Pharmaceutical Data-Driven Discoveries

August 28, 2014 8:30 am | News | Comments

IBM today announced significant advances in Watson's cognitive computing capabilities that are enabling researchers to accelerate the pace of scientific breakthroughs by discovering previously unknown connections in Big Data.    

Amerigen Pharmaceuticals and Ningbo Menovo Pharmaceutical to Collaborate on Generics

August 27, 2014 12:04 pm | News | Comments

Under the terms of the agreement, Amerigen and Menovo will jointly develop products for Amerigen to commercialize in the United States. Menovo will be responsible for manufacturing API and finished product whereas Amerigen will be responsible for clinical, regulatory and commercial activities in the United States.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading